3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
Medulloblastoma
1
Lung Neoplasms
1
Leukemia, Hairy Cell
1
Ependymoma
1
Bulbo-Spinal Atrophy, X-Linked
1
Interventions
pembrolizumab
45
Paclitaxel
8
Cisplatin
8
Carboplatin
8
lenvatinib
7
Pemetrexed
5
Gemcitabine
4
camrelizumab
3
Docetaxel
3
Capecitabine
3
epacadostat
2
avelumab
2
Fluorouracil
2
Cetuximab
2
Acetaminophen
2
vicriviroc
1
sinoporphyrin sodium
1
penpulimab
1
olaparib
1
etoposide phosphate
1
enzalutamide
1
balstilimab
1
apatinib
1
Temozolomide
1
Tadalafil
1
Standard of Care
1
Serotonin 5-HT3 Receptor Antagonists
1
Radiotherapy
1
Radiosurgery
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Histamine Antagonists
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled